Selective Visualization of Cyclooxygenase-2 in Inflammation and Cancer by Targeted Fluorescent Imaging Agents

被引:141
|
作者
Uddin, Md. Jashim [3 ,4 ]
Crews, Brenda C. [3 ,4 ]
Blobaum, Anna L. [3 ,4 ]
Kingsley, Philip J. [3 ,4 ]
Gorden, D. Lee [5 ]
McIntyre, J. Oliver [5 ]
Matrisian, Lynn M. [5 ]
Subbaramaiah, Kotha [6 ]
Dannenberg, Andrew J. [6 ]
Piston, David W. [1 ,2 ]
Marnett, Lawrence J. [1 ,3 ,4 ]
机构
[1] Vanderbilt Univ, Med Ctr, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Dept Phys & Astron, Sch Med, Nashville, TN 37232 USA
[3] Vanderbilt Inst Chem Biol, AB Hancock Jr Mem Lab Canc Res, Dept Biochem, Ctr Mol Toxicol, Nashville, TN USA
[4] Vanderbilt Inst Chem Biol, AB Hancock Jr Mem Lab Canc Res, Dept Chem & Pharmacol, Ctr Mol Toxicol, Nashville, TN USA
[5] Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN USA
[6] Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA
关键词
GROWTH-FACTOR RECEPTOR; IN-VIVO EVALUATION; HUMAN COLON-CANCER; SUBCELLULAR-LOCALIZATION; COX-2; EXPRESSION; PET TRACER; INHIBITION; SYNTHASE-1; PROTEIN; TUMORS;
D O I
10.1158/0008-5472.CAN-09-2664
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Effective diagnosis of inflammation and cancer by molecular imaging is challenging because of interference from nonselective accumulation of the contrast agents in normal tissues. Here, we report a series of novel fluorescence imaging agents that efficiently target cyclooxygenase-2 (COX-2), which is normally absent from cells, but is found at high levels in inflammatory lesions and in many premalignant and malignant tumors. After either i.p. or i.v. injection, these reagents become highly enriched in inflamed or tumor tissue compared with normal tissue and this accumulation provides sufficient signal for in vivo fluorescence imaging. Further, we show that only the intact parent compound is found in the region of interest. COX-2-specific delivery was unambiguously confirmed using animals bearing targeted deletions of COX-2 and by blocking the COX-2 active site with high-affinity inhibitors in both in vitro and in vivo models. Because of their high specificity, contrast, and detectability, these fluorocoxibs are ideal candidates for detection of inflammatory lesions or early-stage COX-2-expressing human cancers, such as those in the esophagus, oropharynx, and colon. Cancer Res; 70(9); 3618-27. (C) 2010 AACR.
引用
收藏
页码:3618 / 3627
页数:10
相关论文
共 50 条
  • [41] Lung cancer and cyclooxygenase-2
    Castelao, JE
    Bart, RD
    DiPerna, CA
    Sievers, EM
    Bremner, RM
    ANNALS OF THORACIC SURGERY, 2003, 76 (04): : 1327 - 1335
  • [42] Cyclooxygenase-2 and colorectal cancer
    DuBois, RN
    COX-2: A NEW TARGET FOR CANCER PREVENTION AND TREATMENT, 2003, 37 : 124 - 137
  • [43] Cyclooxygenase-2 and gastrointestinal cancer
    Mann, JR
    DuBois, RN
    CANCER JOURNAL, 2004, 10 (03): : 145 - 152
  • [44] Cyclooxygenase-2 in lung cancer
    Dubinett, SM
    Sharma, S
    Huang, M
    Dohadwala, M
    Pold, M
    Mao, JT
    COX-2: A NEW TARGET FOR CANCER PREVENTION AND TREATMENT, 2003, 37 : 138 - 162
  • [45] Cyclooxygenase-2 in ovarian cancer
    Song, YS
    Proceedings of the XIX Asian and Oceanic Congress of Obstetrics & Gynecology, 2005, : 171 - 171
  • [46] Cyclooxygenase-2 and Gastric Cancer
    Thiel, Alexandra
    Mrena, Johanna
    Ristimaki, Ari
    CANCER AND METASTASIS REVIEWS, 2011, 30 (3-4) : 387 - 395
  • [47] Cyclooxygenase-2 in lung cancer
    Reckamp, Karen L.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S124 - S125
  • [48] Cyclooxygenase-2 selective inhibitors and prostate cancer: What is the clinical benefit?
    DuBois, RN
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2691 - 2693
  • [49] Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk
    Ashok, Varun
    Dash, Chiranjeev
    Rohan, Thomas E.
    Sprafka, J. Michael
    Terry, Paul D.
    BREAST, 2011, 20 (01): : 66 - 70
  • [50] Cyclooxygenase-2 and inflammation in Alzheimer's disease
    Ho, L
    Kelley, K
    Blanco, C
    Pasinetti, GM
    BIOLOGICAL PSYCHIATRY, 1998, 43 : 65S - 65S